Journal of hepatology
Audio Summaries

Corticosteroid Therapy for Drug-induced Liver Injury: Mind the Gap!

Aug 5, 2026

The authors investigate the efficacy and safety of corticosteroid therapy in treating drug-induced liver injury (DILI), particularly in the context of checkpoint inhibitor-induced liver injury (ChILI). They highlight the lack of evidence supporting corticosteroids' ability to accelerate recovery or improve survival outcomes in DILI, while also noting the potential for adverse effects and delayed resolution when used inappropriately. The paper suggests that corticosteroid-sparing strategies are often more effective and safer for managing ChILI.

Systemic therapy of biliary tract cancer: The road to personalised strategies

Aug 4, 2026

The authors explore the current landscape and future directions of systemic therapy for biliary tract cancers (BTC), aiming to understand how personalized treatment strategies can improve patient outcomes. They highlight the role of precision medicine, particularly targeted therapies for specific genetic mutations, and the challenges in implementing these strategies due to issues like biomarker testing and resistance biology. The review emphasizes the need for optimized diagnostics and innovative trial designs to advance personalized care in BTC.

Reproducibility of Biomarkers in MASLD: A Benchmark for Clinically Meaningful Change in Serially Measured Non-Invasive Tests

Aug 3, 2026

The authors aimed to evaluate the reproducibility of non-invasive tests (NITs) for monitoring disease severity in metabolic-dysfunction associated steatotic liver disease (MASLD) to establish clinically meaningful changes at the patient level. Through a comprehensive analysis of measurement variation across a large cohort, they found that different NITs exhibited varying degrees of reproducibility, with the enhanced liver fibrosis score showing the highest reliability. These findings provide critical insights for the longitudinal monitoring of disease progression and treatment response in clinical practice and drug development.

The changing epidemiology of primary liver cancer in the 21^st century

Aug 1, 2026

The authors investigate the changing epidemiology of primary liver cancer in the 21st century, highlighting a significant increase in incident cases and deaths from 2000 to 2023, despite a prior decline in age-standardized rates. They note a concerning rebound in hepatitis B and C-related liver cancer since 2020, alongside a rapid rise in cases associated with metabolic dysfunction. The study underscores the need for ongoing public health efforts to address the diverse and evolving causes of liver cancer globally.

Low-dose bevacizumab plus atezolizumab enhances transarterial chemoembolization in HCC via correcting vascular-immune niche dysfunction

Jul 31, 2026

This study investigates the vascular and immune microenvironment changes in hepatocellular carcinoma (HCC) following transarterial chemoembolization (TACE) and aims to optimize combination therapy. The authors found that TACE leads to a dysfunctional vascular niche characterized by increased angiogenesis and immunosuppression, primarily driven by PDGFC+ tumor-associated macrophages. They propose that low-dose bevacizumab combined with atezolizumab can normalize this microenvironment, enhance antitumor immunity, and improve clinical outcomes in HCC patients post-TACE.

Non-selective β-blockers reduce bacterial translocation by restoring gut barrier function during experimental cirrhosis

Jul 28, 2026

The authors investigate whether β-adrenergic signaling contributes to gut barrier dysfunction and bacterial translocation in experimental cirrhosis, and if non-selective β-blockers like propranolol can mitigate these effects. Their findings demonstrate that propranolol restores gut barrier integrity and reduces bacterial translocation by stabilizing endothelial VE-cadherin, independent of microbiota changes. This suggests that targeting β-adrenergic hyperactivity may be a viable therapeutic approach in managing gut-liver axis disruptions in cirrhosis.

A framework and shared vocabulary to identify actionable protein biomarkers and enable optimal precision medicine: Myth-Busting with Unicorn Biomarkers

Jul 25, 2026

The authors seek to establish a clear framework and shared vocabulary to differentiate between validated protein biomarkers and unvalidated findings in the context of precision medicine. They emphasize the need for rigorous technical, scientific, and regulatory standards to ensure that only clinically actionable biomarkers are recognized, introducing the concept of "Unicorn Biomarkers" to highlight those with validated multipurpose utility. This framework aims to guide stakeholders in advancing biomarker discovery and development, ultimately enhancing patient care.

Fibrosis regression in chronic liver disease: the pathologist's view

Jul 24, 2026

The authors aim to address the limitations in histological assessment of liver fibrosis regression in chronic liver diseases and the identification of a critical point of no return in advanced fibrosis. They highlight the inadequacies of current semiquantitative staging systems and advocate for improved methodologies, potentially incorporating artificial intelligence, to enhance the evaluation of fibrosis reversal and its clinical significance.

An ABC approach for preoperative staging in perihilar cholangiocarcinoma An international multicenter cohort study

Jul 24, 2026

This study aimed to develop an ABC system for preoperative staging of patients with perihilar cholangiocarcinoma (pCCA) to better predict surgical outcomes and recurrence rates. The authors identified independent prognostic factors such as tumor size, CA19-9 levels, and WHO performance status, demonstrating that higher ABC scores correlate with significantly increased risks of mortality and recurrence. The findings suggest caution in offering surgical resection to patients with high ABC scores, indicating a need for careful patient selection.

Pushing the boundaries of liver resection for liver cancer

Jul 23, 2026

The authors explore how advancements in surgical techniques and oncological principles can expand the eligibility for liver resection in patients with hepatocellular carcinoma (HCC) and intrahepatic cholangiocarcinoma (iCCA), particularly in cases previously deemed unresectable. They emphasize the importance of assessing future liver remnant and functional reserve while integrating systemic and locoregional therapies to improve surgical outcomes. Additionally, the paper discusses the potential impact of new molecular biology insights and treatment strategies on enhancing resectability for liver cancer.